Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8302311 | 0.85 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13491438 | 0.82 | LMNA (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL508753 | 0.79 | SMN1; SMN2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13722386 | 0.77 | PIK3CD (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18073626 | 0.75 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22394487 | 0.70 | LMNA (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14567692 | 0.68 | POLB (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18400798 | 0.68 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8115315 | 0.68 | PKM (0.34) | — | |
| SCHEMBL20936142 | 0.67 | PIK3CD (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278960-A1 | NOVEL ACRIDINIUM SALT AND METHOD FOR PRODUCING SAME | SHIONOGI & CO., LTD. (JP) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278960-A1 | NOVEL ACRIDINIUM SALT AND METHOD FOR PRODUCING SAME | ATL3, CBR3, CLIC1 | CHRM2 282/4885CHRM4 694/4885CHRM5 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.